Adverum Biotechnologies to Present at the ARM 5th Annual Cell & Gene Therapy Investor Day

April 6, 2017

MENLO PARK, Calif., April 06, 2017 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a leading gene therapy company advancing novel medicines to address unmet needs in serious rare and ocular diseases, announced today that Amber Salzman, Ph.D., president and chief executive officer, will present at the Alliance for Regenerative Medicine’s 5th Annual Cell & Gene Therapy Investor Day.

Event:  Alliance for Regenerative Medicine’s Cell & Gene Therapy Investor Day

Date:  April 27, 2017

Time:  5:00 pm EDT

Location:  Boston, MA

A live and replay video webcast of the presentation will be available at

About Adverum Biotechnologies, Inc.
Adverum is a gene therapy company advancing novel medicines that can offer life-changing benefits to patients living with serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat wet age-related macular degeneration (wAMD) and rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE).  Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, the Company generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development. For more information please visit

Contacts for Adverum:

Leone Patterson
Chief Financial Officer
Adverum Biotechnologies, Inc.

Jill Steier
Senior Vice President
The Trout Group LLC

Primary Logo


Adverum Biotechnologies, Inc.